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Public health debates about providing HIV antiretroviral
therapy to impoverished HIV+ populations are based on
the relationship between adherence and risk of drug
resistance to HIV antiretroviral therapy. Early justifica-
tions for withholding antiretroviral therapy from mar-
ginalized domestic populations, such as drug users and
the homeless, were mistaken for two reasons. First,
levels of adherence in marginalized populations were
not much different than the general HIV+ population,
and second, early single protease-based antiretroviral
therapy lead to drug resistance predominately in highly
(80-95%) adherent individuals. In retrospect, HIV antire-
troviral drug resistance during the first decade of effec-
tive therapy was not driven by poor adherence, but
rather by the fact that early regimens were not potent
enough to fully suppress the virus in patients who took
most, if not all, of their medications. The introduction
of more potent ritonavir-boosted protease inhibitor and
non-nucleoside reverse transcriptase inhibitor regimens
have shifted this relationship towards full viral suppres-
sion and cessation of drug resistance at high levels of
adherence.
Similar concerns slowed the provision of HIV antire-
troviral therapy in resource-limited settings based on
the expectations that extreme poverty would lead to
poor adherence and the global spread drug resistant
virus. Data from most studies indicate that these con-
cerns were overstated. Individuals in resource-limited
settings consistently take >90% of their medication,
compared to 70% in resource-rich settings. Successful
adherence can be explained on the practice of indivi-
duals leveraging their social capital to ask friends and
family to overcome structural and economic barriers to
treatment adherence. Furthermore, full viral suppression
is possible in antiretroviral naïve patients on non-
nucleoside reverse transcriptase inhibitors regimens,
typical of resource-limited settings, at moderate levels of
adherence. Rather, the risk of drug resistance in
resource-limited settings appears to be more related
interruptions in therapy due to structural and financial
barriers to drug supply and distribution. These interrup-
tions in therapy lead to nevirapine monotherapy as
nucleoside antiretroviral drug levels (stavudine and lami-
vudine) decay more rapidly than non-nucleoside reverse
transcriptase inhibitor drug levels (nevirapine) following
a treatment interruption ("the nevirapine tail”). While
efforts to sustain and prevent declines in adherence will
be important in resource-limited settings, resistance will
have less to do with forgotten doses, than ensuring a
reliable drug supply and distribution system.
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